CHICAGO — Patients who had a wireless pacing system implanted to receive cardiac resynchronization therapy for the treatment of HF saw positive long-term results comparable to conventional endocardial pacing systems, according to an abstract presented at the Heart Rhythm Society Annual Scientific Sessions.
“The results are very encouraging because it’s the first time we are seeing the long-term outcome of this wireless pacing system and was demonstrated to be safe and feasible for [HF] devices,” Simon James, MRCP, a electrophysiologist at James Cook University Hospital in Middlesbrough, United Kingdom, said in a press release. “By eliminating the challenges that come with leads seen in a conventional pacing system, this novel device provides a new treatment alternative that has the potential to improve the patient’s overall quality of life.”
Researchers analyzed data from 33 patients (mean age, 66 years; 29 men) who underwent implantation of the CRT-P (WiSE; EBR Systems) who previously did not respond to conventional CRT after progressive HF. Other reasons for device implantation included device upgrade (n = 3) and adverse anatomy (n = 20).
Left ventricular capture remained possible for all patients throughout the study, according to the researchers.
Mean energy required for electrical capture was 0.38 mJ at 1 week (standard deviation [SD], 0.47), 0.36 mJ at 1 month (SD, 0.53), 0.33 mJ at 2 months (SD, 0.38), 0.37 mJ at 6 months (SD, 0.39), 0.19 mJ at 1 year (SD, 0.17) and 0.25 mJ at 2 years (SD, 0.21), James and colleagues found.
“The 2-year threshold trends are analogous to those for conventional endocardial pacing systems and provide promising performance efficacy,” James and colleagues wrote in the abstract. – by Darlene Dobkowski
James S, et al. Abstract C-AB34-01. Presented at: Heart Rhythm Society Annual Scientific Sessions; May 10-13, 2017; Chicago.
The researchers report no relevant financial disclosures.